Glycyrrhetinic Acid and Its Derivatives As Potential Alternative Medicine to Relieve Symptoms in Nonhospitalized COVID-19 Patients
Overview
Affiliations
SARS-CoV-2 is highly infectious, and infection by this virus results in COVID-19, manifesting predominantly symptoms in the lower respiratory system. Detection of viral genomic materials by RT-PCR is the gold standard for diagnosis. Suspected COVID-19 patients who had a documented history of exposure and exhibited symptoms, but did not have positive PCR test results, were generally self-quarantined with prescriptions aiming to help attenuate their symptoms. These prescriptions are however neither specific nor highly effective for COVID-19 treatment. Given the rapidly growing pandemic and the overwhelmed medical system, the number of self-quarantined patients is increasing. There is an urgent need of alternative medicine to help patients relieve symptoms during self-quarantine, and to potentially help increase their chances of survival and recovery from the infection. We report here a case of severe COVID-19 that never had a positive PCR test result during disease progression but was confirmed with antibody test post recovery. This patient was self-quarantined and received diammonium glycyrrhizinate (DG), a steroid-like molecule, in combination with vitamin C as alternative medicine. This patient went through severe COVID-19 but eventually recovered upon the implementation of this treatment regimen, suggesting potential therapeutic effects of DG as alternative medicine to help relieve COVID-19 symptoms.
Zhao M, Shi X, Chang J, Wang R, Zhou J, Liu P AAPS PharmSciTech. 2024; 26(1):18.
PMID: 39707118 DOI: 10.1208/s12249-024-03007-1.
Kheirandish E, Mahdizadeh M, Mahdizadeh M, Rezaeitalab F, Yousefi M, Shojaee S Virol J. 2024; 21(1):319.
PMID: 39702335 PMC: 11656726. DOI: 10.1186/s12985-024-02586-6.
A review of typical biological activities of glycyrrhetinic acid and its derivatives.
Chen L, Gong J, Yong X, Li Y, Wang S RSC Adv. 2024; 14(10):6557-6597.
PMID: 38390501 PMC: 10882267. DOI: 10.1039/d3ra08025k.
Zendejas-Hernandez U, Alcantara-Martinez N, Vivar D, Valenzuela F, Sosa Espinoza A, Cervera Ceballos E Front Immunol. 2024; 14:1282280.
PMID: 38283346 PMC: 10811189. DOI: 10.3389/fimmu.2023.1282280.
Integrated Immunopeptidomic and Proteomic Analysis of COVID-19 lung biopsies.
Yin S, Klaeger S, Chea V, Carulli I, Rachimi S, Black K Front Immunol. 2023; 14:1269335.
PMID: 37942334 PMC: 10628763. DOI: 10.3389/fimmu.2023.1269335.